The population is part of a trial result. SURMOUNT-2 examined weight management in adults with type 2 diabetes, not the diabetes-free population of every other obesity study. Primary report
Study snapshot
The blinded, placebo-controlled trial randomized 938 adults to two tirzepatide groups or placebo for 72 weeks. Both active groups achieved greater weight reduction. The treatment-regimen estimand included effects regardless of treatment discontinuation or additional glucose-lowering rescue therapy. Weight change and reaching a specified weight-reduction threshold were coprimary outcomes. Primary report
Weight management in people who already have diabetes
SURMOUNT-2 randomized 938 adults with type 2 diabetes and a body mass index of at least 27 kg/m². At 72 weeks, average weight changes in its two tirzepatide groups were minus 12.8% and minus 14.7%, compared with minus 3.2% with placebo. Placebo-adjusted differences were minus 9.6 percentage points (95% confidence interval minus 11.1 to minus 8.1) and minus 11.6 points (minus 13.0 to minus 10.1). Its treatment-regimen analysis included outcomes regardless of discontinuation or rescue glucose-lowering therapy. SURMOUNT-2 primary abstract, Methods and Findings.
Our appraisal: do not compare percentages without matching the question
Cross-trial weight-loss percentages can differ because of population, background treatment, follow-up, and analysis strategy. A lower or higher percentage in a separate trial does not by itself establish that one population responds causally differently. That claim requires a suitable comparative analysis.
The estimand is especially important. A question about assignment to a treatment strategy, including discontinuation and rescue, differs from a hypothetical question about remaining on treatment throughout. Neither should be selected merely because it produces a more attractive number.
Mean weight change and threshold attainment also communicate different things. A group average does not tell every individual's outcome, while a responder percentage depends on where the threshold is set. Reporting both can be useful if their definitions remain clear.
Full review should inspect missing-data assumptions, rescue medication, adverse events, and the distribution of responses. Weight reduction should not be expanded into unmeasured claims about survival, complications, or permanent disease reversal. This page appraises a trial; it does not choose a treatment for an individual.
Frequently asked questions
Did participants already have type 2 diabetes?
Yes.
Was the trial placebo controlled and blinded?
Yes.
Did the active groups reduce weight more than placebo?
The reported comparisons favored tirzepatide.
Does the mean predict each person's response?
No.
Does treatment discontinuation matter to the analysis?
Yes. The estimand specifies how such events are handled.
Can separate trial percentages prove a population interaction?
No.
What needs close review?
The population, estimand, missing-data assumptions, rescue therapy, and complete benefit-risk results.